Role of diuretics and ultrafiltration in congestive heart failure

Pharmaceuticals

Volumn 6, Issue 7, 2013, Pages 851-866

  Shchekochikhin, Dmitry ^a   Al Ammary, Fawaz ^a   Lindenfeld, Joann ^a   Schrier, Robert ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiac failure; Diuretic combinations; Diuretic resistance; Ultrafiltration

Indexed keywords

ACETAZOLAMIDE; BENDROFLUMETHIAZIDE; BUMETANIDE; BUTIZIDE; CALCIUM; CHLOROTHIAZIDE; CONIVAPTAN; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; METOLAZONE; MINERALOCORTICOID ANTAGONIST; QUINETHAZONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; VASOACTIVE AGENT; VASODILATOR AGENT;

CALCIUM BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; FLUID RETENTION; GOUT; HEART FAILURE; HEART OUTPUT; HUMAN; HYPERURICEMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LENGTH OF STAY; LOW DRUG DOSE; METABOLIC ALKALOSIS; METABOLIC DISORDER; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERDIURESIS; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POTASSIUM WASTING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLOW CONTINUOUS VENOVENOUS ULTRAFILTRATION; SODIUM RESTRICTION; SODIUM RETENTION;

EID: 84879831704     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6070851     Document Type: Review

References (81)

1. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson, T.B, Ford, E.; Furie, K.; Gillespie, C, Go, A, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119, 480-486.
2. Jencks, S.F.; Williams, M.V.; Coleman, E.A. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 2009, 360, 1418-1428.
3. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2009, 53, e1-e90.
4. Adams, K.F., Jr; Fonarow, G.C.; Emerman, C.L.; LeJemtel, T.H.; Costanzo, M.R.; Abraham, W.T.; Berkowitz, R.L.; Galvao, M.; Horton, D.P.; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 2005, 149, 209-216.
5. Gheorghiade, M.; Filippatos, G.L.; Burnett, J. Congestion in acute heart failure syndromes: An essential target of evaluation and treatment. Am. J. Med. 2006, 119, S3-S10.
6. Zile, M.R.; Bennett, T.D.; St John Sutton, M.; Cho, Y.K.; Adamson, P.B.; Aaron, M.F.; Aranda, J.M., Jr; Abraham, W.T.; Smart, F.W; Stevenson, L.W, et al. Transition from chronic compensated to acute decompensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008, 118, 1433-1441.
7. Gaasch, W.H.; Zile, M.R. Left ventricular structural remodeling in health and disease: With special emphasis on volume, mass, and geometry. J. Am. Coll. Cardiol. 2011, 58, 1733-1740.
8. Schrier, R.W. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J. Am. Coll. Cardiol. 2006, 47, 1-8.
9. Linden, R.J.; Kappagoda, C.T. Atrial receptors and renal blood flow. In Atrial Receptors; Cambridge University Press: Cambridge, UK, 1982.
10. Packer, M. Neurohormone interaction and adaptations in congestive HF. Circulation 1988, 77, 721-730.
11. Sarraf, M.; Masoumi, A.; Schrier, R.W. CRS in Acute Decompensated HF. Clin. J. Am. Soc. Nephrol. 2009, 4, 2013-2026.
12. Schrier, R.W. Body fluid volume regulation in health and disease: A unifying hypothesis. Ann. Intern. Med. 1990, 113, 155-159.
13. Schrier, R.W.; Abraham, W.T. Hormones and hemodynamics in HF. N. Engl. J. Med. 1999, 341, 577-578.
14. Blankstein, R.; Bakris, G.L. Renal hemodynamic changes in HF. Heart. Fail. Clin. 2008, 4, 411-423.
15. Weber, K. Mechanisms of disease: Aldosterone in chronic HF. N. Engl. J. Med. 2001, 345, 1689-1697.
16. Cohn, J.N.; Levine, T.V.; Olivari, M.T.; Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive HF. N. Engl. J. Med. 1984, 311, 819-823.
17. Schrier, R.W.; Berl, T.; Anderson, R.J. Osmotic and nonosmotic control of vasopressin release. Am. J. Physiol. 1979, 236, F321-F332.
18. Brater, D.C. Update in diuretic therapy: Clinical pharmacology. Semin. Nephrol. 2011, 31, 483-494.
19. Chennavasin, P.; Seiwell, R.; Brater, D.C.; Liang, W.M.M. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 1979, 6, 187-195.
20. Odlind, B.; Beerman, B. Renal tubular secretion and effects of furosemide. Clin. Pharmacol. Ther. 1980, 27, 784-790.
21. Brater, D.C. Diuretic pharmacokinetics and pharmacodynamics. In The in vivo Study of Drug Action (Principles and Applications of Kinetic-Dynamic Modelling); van Boxtel, C.J., Holford, N.H.G., Danhof, M., Eds. Elsevier Science Publishers: Amsterdam, The Netherlands, 1992.
22. Murray, M.D.; Haag, K.M.; Black, P.K.; Hall, S.D.; Brater, D.C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997, 17, 98-106.
23. Wilcox, C.S.; Mitch, W.E.; Kelly, R.A.; Skorecki, K.; Meyer, T.W.; Friedman, P.A.; Souney, P.F. Response of the kidney to furosemide (I. Effects of salt intake and renal compensation). J. Lab. Clin. Med. 1983, 102, 450-458.
24. Salvador, D.R.; Rey, N.R.; Ramos, G.C.; Punzalan, F.E. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005, 20, CD003178.
25. Felker, G.M.; Lee, K.L.; Bull, D.A.; Redfield, M.M.; Stevenson, L.W.; Goldsmith, S.R.; LeWinter, M.M.; Deswal, A.; Rouleau, J.L, Ofili, E.O. et al. Diuretic strategies in patients with acute decompensated HF. N. Engl. J. Med. 2011, 364, 797-805.
26. Heart Failure Society of America; Lindenfeld, J.; Albert, N.M.; Boehmer, J.P.; Collins, S.P.; Ezekowitz, J.A.; Givertz, M.M.; Katz, S.D.; Klapholz, M, Moser, D.K. et al. Executive summary: HFSA 2010 comprehensive HF practice guidelines. J. Card Fail. 2010, 16, 475-539.
27. Jentzer, J.C.; DeWald, T.A.; Hernandez, A.F. Combination of loop diuretics with thiazide-type diuretics in heart failure. J. Am. Coll. Cardiol. 2010, 56, 1527-1534.
28. Kim, G.H. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am. J. Nephrol. 2004, 24, 595-605.
29. Ellison, D.H. The physiologic basis of diuretic synergism: Its role in treating diuretic resistance. Ann. Intern. Med. 1991, 114, 886-894.
30. Sica, D.A.; Gehr, T.W. Diuretic combinations in refractory oedema states: Pharmacokineticpharmacodynamic relationships. Clin. Pharmacokinet. 1996, 30, 229-249.
31. Sica, D.A. Metolazone and its role in edema management. Congest. Heart Fail. 2003, 9, 100-105.
32. Channer, K.S.; McLean, K.A.; Lawson-Matthews, P.; Richardson, M. Combination diuretic treatment in severe heart failure: A randomized controlled trial. Br. Heart J. 1994, 71, 146-150.
33. Asscher, A.W. Treatment of frusemide resistant edema with metolazone. Clin. Trials J. 1974, 4, 134-139.
34. Khan, M.I. Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can. Med. Assoc. J. 1980, 123, 883-887
35. Javaheri, S. Acetazolamide improves central sleep apnea in heart failure: A double-blind, prospective study. Am. J. Respir. Crit. Care Med. 2006, 173, 234-237.
36. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999, 341, 709-717.
37. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348, 1309-1321.
38. Zannad, F.; McMurray, J.J.; Krum, H.; van Veldhuisen, D.J.; Swedberg, K.; Shi, H.; Vincent, J.; Pocock, S.J.; Pitt, B. EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364, 11-21.
39. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 1996, 78, 902-907.
40. Juurlink, D.; Mamdani, M.; Lee, D.S; Kopp, A.; Austin, P.C.; Laupacis, A; Redelmeier, D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351, 543-551.
41. Li, W.; Struthers, A.D.; Fahey, T.; Watson, A.D.; MacDonald, T.M. Spironolactone use and renal toxicity: Population based longitudinal analys is. BMJ 2010, 340, c1768.
42. Shchekochikhin, D.; Lindenfeld, J.; Schrier, R.W. Increased Spironolactone in Advanced HF: Effect of Doses Greater Than 25 mg/day on Plasma Potassium Concentration. Cardiorenal. Med. 2013, 3, 1-6.
43. Udelson, J.E.; Smith, W.B.; Hendrix, G.H.; Painchaud, C.A.; Ghazzi, M.; Thomas, I.; Ghali, J.K.; Selaru, P.; Chanoine, F.; Pressler, M.L.; Konstam, M.A. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104, 2417-2423.
44. Schrier, R.W.; Gross, P.; Gheorghiade, M.; Berl, T.; Verbalis, J.G.; Czerwiec, F.S.; Orlandi, C. For the SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006, 355, 2099-2112.
45. Gheorghiade, M.; Niazi, I.; Ouyang, J.; Czerwiec, F.; Kambayashi, J.; Zampino, M.; Orlandi, C.; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 2003, 107, 2690-2696.
46. Gheorghiade, M.; Gattis, W.A.; O'Connor, C.M.; Adams, K.F., Jr; Elkayam, U.; Barbagelata, A.; Ghali, J.K.; Benza, R.L.; McGrew, F.A; Klapholz, M, et al. Acute and chronic therapeutic impact of a vasopressin antagonist in congestive heart failue (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004, 291, 1963-1971.
47. Udelson, J.E.; McGrew, F.A.; Flores, E.; Ibrahim, H.; Katz, S.; Koshkarian, G.; O'Brien, T.; Kronenberg, M.W.; Zimmer, C.; Orlandi, C.; Konstam, M.A. Multicenter, randomized, doubleblind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 2007, 49, 2151-2159.
48. Udelson, J.E.; Orlandi, C; Ouyang, J.; Krasa, H.; Zimmer, C.A.; Frivold, G.; Haught, W.H.; Meymandi, S.; Macarie, C, Raef, D, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 2008, 52, 1540-1545.
49. Konstam, M.A.; Gheorghiade, M.; Burnett, J.C., Jr; Grinfeld, L.; Maggioni, A.P.; Swedberg, K.; Udelson, J.E.; Zannad, F.; Cook, T.; Ouyang, J., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007, 297, 1319-1331.
50. Schrier, R.W. Use of diuretics in heart failure and cirrhosis. Semin. Nephrol. 2011, 31, 503-512.
51. Ellison, D.H. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001, 96, 132-143.
52. Quamme, G.A. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am. J. Physiol. 1981, 241, F340-F347.
53. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestiveheart failure: A randomized controlled trial. JAMA 2002, 287, 1531-1540.
54. Bansal, S.; Lindenfeld, J.A.; Schrier, R.W. Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist? Circ. Heart Fail. 2009, 2, 370-376.
55. Knauf, H.; Mutschler, E. Sequential Nephron Blockade Breaks Resistance to Diuretics in Edematous States. J. Cardiovasc. Pharm. 1997, 29, 367-372.
56. Brater, D.C. Diuretic Resistance: Mechanisms and Therapeutic Strategies. Cardiology 1994, 84 (suppl. 2), 57-67.
57. Kirchner, K.A. Mechanisms of diuretic resistance in nephrotic syndrome. In: Diuretics IV, Chemistry, Pharmacology and Clinical Applictions; Puschett, J.B., Greenberg, A., Eds.; Excerpta Medica pupl.: Amsterdam, The Netherlands, 1993, pp. 435-443.
58. Voelker, J.R.; Brater, D.C. Diuretics: Applied pharmacokinetics and drug resistance. In The Regulation of Sodium and Chloride Balance; Seldin, D.W., Giebisch, G., Eds.; Raven Press: New York, NY, USA, 1990; pp. 503-524.
59. + load in the nephron segment determines the ceiling quality of a diuretic. In Diuretics III, Chemistry, Pharmacology, and Clinical Applications; Puschett, J.B., Greenberg, A., Eds.; Elsevier: New York, NY, USA, 1989; pp. 359-362.
60. Schrier, R.W. Pathogenesis of sodium and water retention in high and low output cardiac failure, cirrhosis, nephrotic syndrome, and pregnancy. N. Engl. J. Med. 1988, 319, 1065-1072.
61. Ellison, D.H.; Velazquez, H.; Wright, F.S. Adaption of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J. Clin. Invest. 1989, 83, 113-126.
62. Gabrielsen, A.; Bie, P.; Holstein-Rathlou, N.H.; Christensen, N.J.; Warberg, J.; Dige-Petersen, H.; Frandsen, E.; Galatius, S.; Pump, B, Sørensen, V.B, et al. Neuroendocrine and renal effects of intravascular volume expansion in compensated heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281, R459-R467.
63. Spahr, L.; Villeneuve, J.P.; Tran, H.K.; Pomier-Layrargues, G. Furosemide-Induced Natriuresis as a Test To Identify Cirrhotic Patients With Refractory Ascites. Hepatology 2001, 33, 28-31
64. Fang, L.S.; Sirota, R.A.; Ebert, T.H.; Lichtenstein, N.S. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch. Intern. Med. 1980, 140, 531-533.
65. Silverstein, M.E.; Ford, C.A.; Lysaght, M.J.; Henderson, L.W. Treatment of severe fluid overload by ultrafiltration. N. Engl. J. Med. 1974, 291, 747-751.
66. Bart, B.A.; Boyle, A.; Bank, A.J.; Anand, I.; Olivari, M.T.; Kraemer, M.; Mackedanz, S.; Sobotka, P.A.; Schollmeyer, M.; Goldsmith, S.R. Ultrafiltration versus usual care for hospitalized patients with heart failure: The Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J. Am. Coll. Cardiol. 2005, 46, 2043-2046
67. Pepi, M.; Marenzi, G.C.; Agostoni, P.G.; Doria, E.; Barbier, P.; Muratori, M.; Celeste, F.; Guazzi, M.D. Sustained cardiac diastolic changes elicited by ultrafiltration in patients with moderate congestive heart failure: Pathophysiological correlates. Br. Heart J. 1993, 70, 135-140.
68. Jaski, B.E.; Ha, J.; Denys, B.G. Trupp, R.J.; Abraham, W.T. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J. Card. Fail. 2003, 9, 227-231.
69. Agostoni, P.G.; Marenzi, G.C.; Pepi, M.; Doria, E.; Salvioni, A.; Perego, G.; Lauri, G.; Giraldi, F.; Grazi, S.; Guazzi, M.D. Isolated ultrafiltration in moderate congestive heart failure. J. Am. Coll. Cardiol. 1993, 21, 424-431.
70. Costanzo, M.R.; Saltzberg, M.; O'Sullivan, J.; Sobotka, P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J. Am. Coll. Cardiol. 2005, 46, 2047-2051.
71. Rogers, H.L.; Marshall, J.; Bock, J.; Dowling, T.C.; Feller, E.; Robinson, S.; Gottlieb, S.S. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J. Card. Fail. 2008, 14, 1-5
72. Constanzo, M.R.; Guglin, M.E.; Saltzberg, M.T.; Jessup, M.L.; Bart, B.A.; Teerlink, J.R.; Jaski, B.E.; Fang, J.C.; Feller, E.D, Haas, G.J, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated HF. J. Am. Coll. Card. 2007, 49, 675-683.
73. Costanzo, M.R.; Saltzberg, M.T.; Jessup, M.; Teerlink, J.R.; Sobotka, P.A.; Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: Results from UNLOAD. J. Card. Fail. 2010, 16, 277-284.
74. Marenzi, G.; Grazi, S.; Giraldi, F.; Lauri, G.; Perego, G.; Guazzi, M.; Salvioni, A.; Guazzi, M.D. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive HF: Effects of extracorporeal ultrafiltration. Am. J. Med. 1993, 94, 49-56.
75. Patarroyo, M.; Wehbe, E.; Hanna, M.; Taylor, D.O.; Starling, R.C.; Demirjian, S.; Tang, W.H. Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J. Am. Coll. Cardiol. 2012, 60, 1906-1912.
76. Bart, B.A.; Goldsmith, S.R.; Lee, K.L.; Givertz, M.M.; O'Connor, C.M.; Bull, D.A.; Redfield, M.M.; Deswal, A.; Rouleau, J.L, LeWinter, M.M, et al. Ultrafiltration in decompensated HF with CRS. N. Engl. J. Med. 2012, 367, 2296-2304.
77. Aronson, D.; Burger, A.J. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated HF. J. Card. Fail. 2010, 16, 541-547.
78. Fauchauld, P. Effects of ultrafiltration of body fluid and transcapillary colloid osmotic gradient in hemodialysis patients, improvements in dialysis therapy. Contrib. Nephr. 1989, 74, 170-175.
79. Fiaccadori, E.; Regolisti, G.; Maggiore, U.; Parenti, E.; Cremaschi, E.; Detrenis, S.; Caiazza, A.; Cabassi, A. Ultrafiltration in heart failure. Am. Heart J. 2011, 161, 439-449.
80. Nakayama, M. Nonuremic indication for peritoneal dialysis for refractory heart failure in cardiorenal syndrome type II: Review and perspective. Perit. Dial. Int. 2013, 33, 8-14.
81. Regolisti, G.; Fiaccadori, E. Ultrafiltration in acute decompensated heart failure: Friend or foe for the kidney? J. Nephrol. 2013, 26, 421-426.